Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic Rhinitis
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In clinical trials for treatment of allergic rhinitis a significant reduction of the total
symptom score compared to baseline has been demonstrated by using nasal budesonide.Previous
results in adults show that the assessment and monitoring del nasal fractional exhaled nitric
oxide (nFeNO) is useful in controlling inflammation of nasal allergic rhinitis.
Primary objective of this study is to evaluate efficacy of nasal budesonide (aqueous
solution) on the nasal inflammation marker (nFeNO).
Secondary outcomes are the evaluation of: changes in total nasal symptom score (Total Symptom
Score, T5SS), changes in cell counts in nasal lavage (LN) and the changes reported sleep
quality (Pittsburgh Sleep Quality Index, PSQI).
Phase:
Phase 4
Details
Lead Sponsor:
Istituto per la Ricerca e l'Innovazione Biomedica Stefania La Grutta, MD